Table 1.
Incident POAF | |||
---|---|---|---|
Variable |
No (N = 122) |
Yes (N = 127) |
P-value |
Age, (mean ± standard deviation) years | 60.4 ± 16.4 | 70.6 ± 10.7 | 0.001 |
Male, n (%) | 79 (64.8%) | 77 (60.6%) | 0.59 |
BMI, (mean ± standard deviation) kg/m2 | 24.9 ± 3.6 | 26.8 ± 4.5 | 0.001 |
Arterial hypertension, n (%) | 61 (50%) | 93 (73.2%) | 0.001 |
Diabetes, n (%) | 17 (13.9%) | 23 (18.1%) | 0.37 |
Creatinine, (mean ± standard deviation) mg/dL | 0.88 ± 0.32 | 1.06 ± 0.91 | 0.038 |
TSH, (mean ± standard deviation) mU/L | 2.69 ± 4.33 | 1.96 ± 1.69 | 0.13 |
ACE-I, n (%) | 43 (35.2%) | 47 (33.8%) | 0.85 |
Statins, n (%) | 27 (22.2%) | 39 (30.7%) | 0.15 |
LA diameter, (mean ± standard deviation) mm | 39.2 ± 8.1 | 40.1 ± 10.1 | 0.70 |
LA area, (mean ± standard deviation) cm2 | 23.9 ± 5.9 | 23.6 ± 5.9 | 0.69 |
LVEF, (mean ± standard deviation) % | 58.6 ± 9.8 | 57.6 ± 7.9 | 0.41 |
CABG, n (%) | 20 (16.4) | 31 (24.4) | 0.12 |
Operation time, (mean ± standard deviation) minutes | 212 ± 74 | 227 ± 100 | 0.16 |
Clamp time, (mean ± standard deviation) minutes | 70 ± 34 | 76 ± 32 | 0.13 |
Cardiopulmonary bypass time, (mean ± standard deviation), minutes | 97 ± 51 | 101 ± 43 | 0.56 |
Mitral valve repair, n (%) | 31 (25.4) | 28 (22.0) | 0.53 |
Tricuspid valve repair, n (%) | 10 (8.2) | 8 (6.3) | 0.56 |
Aortic valve replacement, n (%) | 49 (40.2) | 50 (39.4) | 0.90 |
Mitral valve replacement, n (%) | 12 (9.8) | 9 (7.1) | 0.44 |
Tricuspid valve replacement, n (%) | 1 (0.8) | 0 | 0.49 |
Morrow septal myectomy, n (%) | 3 (2.5) | 5 (3.9) | 0.72 |
Atrial septal defect closure, n (%) | 4 (3.3) | 3 (2.4) | 0.72 |
Ascendant aorta replacement, n (%) | 10 (8.2) | 9 (7.1) | 0.74 |
Bentall procedure, n (%) | 12 (9.8) | 31 (24.4) | 0.023 |
Ventricular septal defect closure, n (%) | 2 (1.6) | 0 | 0.24 |
Pericardial effusion, n (%) | 36 (29.8%) | 35 (27.3) | 0.67 |
Pleural effusion, n (%) | 34 (28.1%) | 33 (26.0%) | 0.68 |
POAF Post-operative atrial fibrillation, BMI Body mass index, TSH Thyroid stimulating hormone, ACE-I Angiotensin Converting Enzyme inhibitors, LA Left atrium, LVEF Left ventricular ejection fraction, CABG Coronary artery bypass graft